S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
NYSEAMERICAN:CVM

CEL-SCI - CVM Stock Forecast, Price & News

$2.68
-0.02 (-0.74%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.63
▼
$2.73
50-Day Range
$2.29
▼
$5.23
52-Week Range
$1.88
▼
$6.51
Volume
37,979 shs
Average Volume
107,882 shs
Market Capitalization
$117.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

CEL-SCI MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
497.0% Upside
$16.00 Price Target
Short Interest
Bearish
11.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to $0.28 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

See Top Rated MarketRank™ Stocks Here
CVM stock logo

About CEL-SCI (NYSEAMERICAN:CVM) Stock

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Receive CVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CVM Stock News Headlines

January 22, 2023 | thestreet.com
CEL-SCI Stock Gaps Down On Today's Open (CVM)
January 3, 2023 | finance.yahoo.com
CVM: A New Year Ahead
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
October 19, 2022 | finance.yahoo.com
Global Orphan Drugs Market to Reach $545.4 Billion by 2027 - Yahoo Finance
October 18, 2022 | nasdaq.com
Pre-market Movers: AVEO, RMED, GRNA, ARC, INPX… - Nasdaq
October 18, 2022 | globenewswire.com
Global Orphan Drugs Market to Reach $545.4 Billion by 2027 - GlobeNewswire
October 18, 2022 | rttnews.com
Pre-market Movers: AVEO, RMED, GRNA, ARC, INPX… - RTTNews
October 17, 2022 | businesswire.com
CEL-SCI'S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment - Business Wire
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
October 10, 2022 | finance.yahoo.com
Head and Neck Cancer Clinical Trial Pipeline: Analysis of 130+ Key Companies Working in the Domain | DelveInsight - Yahoo Finance
September 30, 2022 | seekingalpha.com
CEL-SCI's (CVM) Multikine - Potential Game-Changing Cancer Drug On The Horizon - Seeking Alpha
September 27, 2022 | finance.yahoo.com
Head and Neck Cancer Market to Surge at a CAGR of 5.1% by 2032 | DelveInsight - Yahoo Finance
September 27, 2022 | bloomberg.com
Head and Neck Cancer Market to Surge at a CAGR of 5.1% by 2032 | DelveInsight - Bloomberg
September 12, 2022 | businesswire.com
CEL-SCI'S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer - Business Wire
September 12, 2022 | seekingalpha.com
CEL-SCI says neoadjuvant multikine shows response in head/neck cancer in trial - Seeking Alpha
September 12, 2022 | finance.yahoo.com
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
September 9, 2022 | seekingalpha.com
CEL-SCI to soon address FDA concerns on cancer therapy
September 8, 2022 | proactiveinvestors.com
CEL-SCI Corp letter to shareholders details positive results from Phase 3 study of Multikine - Proactive Investors USA
September 7, 2022 | benzinga.com
CEL-SCI (CVM) – Cel-Sci Corporation Issues Letter to Shareholders; Multikine Reduced And Eliminated Tumor - Benzinga
August 29, 2022 | benzinga.com
CVM: ClinicalTrials Submission - Benzinga
August 24, 2022 | finance.yahoo.com
Peloton to sell some fitness equipment on Amazon - Yahoo Finance
August 24, 2022 | finance.yahoo.com
CVM: ClinicalTrials Submission
August 19, 2022 | finance.yahoo.com
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov - Yahoo Finance
August 19, 2022 | businesswire.com
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov - Business Wire
August 19, 2022 | streetinsider.com
CEL-SCI Corp (CVM) Announces Phase 3 Multikine Head and Neck Cancer Results Posted on Clinicaltrials.gov - StreetInsider.com
August 16, 2022 | nz.finance.yahoo.com
CEL-SCI Corporation (CVM)
August 15, 2022 | seekingalpha.com
Cel-Sci GAAP EPS of -$0.66 (NYSE:CVM) - Seeking Alpha
See More Headlines
Receive CVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CVM Company Calendar

Last Earnings
12/28/2022
Today
2/05/2023
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
9/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CVM
CUSIP
N/A
CIK
725363
Web
www.cel-sci.com
Phone
(703) 506-9460
Fax
703-506-9471
Employees
2,020
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+497.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,360,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-76.64%
Return on Assets
-55.12%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
7.71
Quick Ratio
7.17

Sales & Book Value

Annual Sales
$560,000.00
Price / Sales
209.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
2.05

Miscellaneous

Outstanding Shares
43,680,000
Free Float
36,443,000
Market Cap
$117.06 million
Optionable
Optionable
Beta
1.68

Key Executives

  • Geert R. Kersten
    CEO, Chief Financial Officer, Treasurer & Director
  • Patricia B. Prichep
    Secretary & Senior Vice President-Operations
  • Eyal Talor
    Chief Scientific Officer
  • William Jones
    Vice President-Quality Assurance
  • Daniel H. Zimmerman
    Senior VP-Research & Cellular Immunology

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













CVM Stock - Frequently Asked Questions

Should I buy or sell CEL-SCI stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CVM shares.
View CVM analyst ratings or view top-rated stocks.

What is CEL-SCI's stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month price targets for CEL-SCI's stock. Their CVM share price forecasts range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 497.0% from the stock's current price.
View analysts price targets for CVM or view top-rated stocks among Wall Street analysts.

Are investors shorting CEL-SCI?

CEL-SCI saw a decrease in short interest during the month of December. As of December 30th, there was short interest totaling 5,070,000 shares, a decrease of 8.8% from the December 15th total of 5,560,000 shares. Based on an average daily trading volume, of 181,500 shares, the days-to-cover ratio is presently 27.9 days.
View CEL-SCI's Short Interest.

When is CEL-SCI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our CVM earnings forecast.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) released its earnings results on Wednesday, December, 28th. The company reported ($0.21) earnings per share for the quarter.

When did CEL-SCI's stock split?

CEL-SCI shares reverse split on the morning of Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Molecular Templates (MTEM), Gilead Sciences (GILD), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA), VBI Vaccines (VBIV) and CymaBay Therapeutics (CBAY).

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of institutional and retail investors. Top institutional shareholders include D.A. Davidson & CO. (0.87%), Cutter & CO Brokerage Inc. (0.20%), Threadgill Financial LLC (0.04%), Threadgill Financial LLC (0.04%), Simplex Trading LLC (0.00%) and Ingalls & Snyder LLC (0.03%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, John Cipriano, Patricia B Prichep, Peter R Young and Robert Eugene Watson.
View institutional ownership trends.

How do I buy shares of CEL-SCI?

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $2.68.

How much money does CEL-SCI make?

CEL-SCI (NYSEAMERICAN:CVM) has a market capitalization of $117.06 million and generates $560,000.00 in revenue each year. The company earns $-36,360,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does CEL-SCI have?

The company employs 2,020 workers across the globe.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The official website for the company is www.cel-sci.com. The company can be reached via phone at (703) 506-9460, via email at gdewindt@cel-sci.com, or via fax at 703-506-9471.

This page (NYSEAMERICAN:CVM) was last updated on 2/5/2023 by MarketBeat.com Staff